Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators expect to find that different intensity and altitude exposure levels will show what kind of intermittent exposure protocol is more beneficial to athletes and healthy individuals that experience acute exposure to altitude during exercise. This may furthermore be related to acute altitude exposure for recreational exercise use as well.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Effect of heart rate training in simulated altitude | Experimental | Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining >65% max heart rate during room air based maximal peak work. |
|
| Effect of saturation of oxygen training in simulated altitude | Experimental | Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining 40-60% of max work rate during room air work rate and based upon saturation of oxygen of between 70-80%. |
|
| Effect of optimized training in simulated altitude | Active Comparator | Participants will perform the more beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether it improves elite athlete's training status at altitude. |
|
| Effect of placebo training in non-simulated altitude | Placebo Comparator | Participants will perform placebo beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether the optimized protocol truely improves elite athlete's training status at altitude. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Simulated altitude | Other | Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in hemoglobin | Baseline, 2-week, 4-week, 6-week, and 8-week | |
| Change in hematocrit | Baseline, 2-week, 4-week, 6-week, and 8-week | |
| Change in erythropoietin | Baseline, 2-week, 4-week, 6-week, and 8-week |
| Measure | Description | Time Frame |
|---|---|---|
| Change in peak VO2 | Change from maximal exercise test performed at sea level | Baseline and 6- and 8-week |
| Change in cycling performance at altitude | change in aerobic/anaerobic cycling performance at altitude |
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Courtney M Wheatley | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | United States |
Not provided
| Label | URL |
|---|---|
| Mayo Clinic Clinical Trials | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000532 | Altitude Sickness |
| ID | Term |
|---|---|
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo simulated altitude | Other | Participants will exercise at sea level at similar percentage of intensities to the simulated altitude group. |
|
| Baseline and 6- and 8-week |